AcelRx touts Dsuvia data for burn victims

AcelRx Pharmaceuticals (NSDQ:ACRX) said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or injury.

The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in any country.

Get the full story at our sister site, Drug Delivery Business News.

The post AcelRx touts Dsuvia data for burn victims appeared first on MassDevice.

from MassDevice http://ift.tt/2koHxvf